Back to top

genomics: Archive

Ekta Bagri

3 Promising Genomics Stocks to Keep an Eye On in 2025

Investors interested in the Genomics and Synthetic Biology theme should keep an eye on MGTX, BEAM and KRYS.

BEAMNegative Net Change NTLANegative Net Change KRYSPositive Net Change MGTXNo Net Change

Sundeep Ganoria

CRISPR Therapeutics vs. Intellia: Which Gene Editing Stock Holds More Potential?

CRSP edges ahead of NTLA with the only approved CRISPR therapy, stronger pipeline breadth and recent stock gains.

REGNPositive Net Change VRTXPositive Net Change NTLANegative Net Change CRSPNegative Net Change

Sundeep Ganoria

Can Casgevy Deliver a Turnaround for CRISPR Therapeutics?

CRSP bets on Casgevy to drive growth, but its extremely high price tag and slow rollout test investor patience in a crowded field.

NVSPositive Net Change BMYPositive Net Change VRTXPositive Net Change BEAMNegative Net Change CRSPNegative Net Change